Building Blocks

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

6-Nitro-2,3-xylidine is a molecule that has been synthesized using organocatalytic methods. This compound is an electron acceptor and a strong nucleophile, which can be used for the synthesis of chiral derivatives. As an organocatalyst, 6-nitro-2,3-xylidine can be used to sulfonate aldehydes with high stereoselectivity. The molecular orbital diagram shows that the antibonding interaction is stronger than the bonding interaction between this compound and chloride.

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

Versatile small molecule scaffold

1-(2-Nitro-phenyl)-piperazine is a chemical compound that is found in plants of the Primulaceae family, such as Arnica montana. It has been shown to have anti-inflammatory properties and may be useful for the treatment of inflammatory bowel disease and alopecia areata. 1-(2-Nitro-phenyl)-piperazine inhibits nitric oxide synthesis by binding to plasma glucose and forming a complex that cannot be broken down by hydrochloric acid. This complex inhibits the enzyme nitrate reductase, which converts nitric oxide into nitrite. Nitrite then reacts with erythrocytes to form methemoglobin, which reduces the oxygen carrying capacity of red blood cells (RBCs). Inhibition of nitric oxide production leads to decreased inflammation and an improvement in symptoms associated with inflammatory bowel disease and alopecia areata.

Versatile small molecule scaffold

Methyl 8-aminooctanoate is a fatty acid amide that inhibits the HIV virus by binding to its receptor. Methyl 8-aminooctanoate has been shown to inhibit the production of human immunodeficiency virus (HIV) in vitro, which may be due to its ability to inhibit the interaction between HIV and its receptor. Methyl 8-aminooctanoate is metabolized by esterases in vivo and excreted in urine. The pharmacokinetic properties of this drug have been evaluated in humans and optimized for a long-chain fatty ester form.